Integrating Machine Learning with Computational Fluid Dynamics Models of Orally Inhaled Drug Products (U01) Clinical Trials Not Allowed
Food and Drug Administration · Department of Health and Human Services
At a glance
Integrating Machine Learning with Computational Fluid Dynamics Models of Orally Inhaled Drug Products (U01) Clinical Trials Not Allowed is a forecasted federal grant opportunity from the Food and Drug Administration (Department of Health and Human Services). The agency has forecast this opportunity but has not yet set an application deadline. Total estimated funding is $600K across about 1 awards. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 9 more. Cost sharing is not required. It is funded under Assistance Listing 93.103 (Food and Drug Administration Research).
Summary assembled from the official notice's fields. The official notice governs.
Key facts
- Posted
- Nov 20, 2023
- Est. close date
- Not listed
- Award floor
- Not specified
- Award ceiling
- Not specified
- Est. total funding
- $600,000
- Implied average award
- $600,000 calculated
- Expected awards
- 1
- Cost sharing
- Not required
- Funding instrument
- Grant, Cooperative Agreement
- Opportunity category
- Discretionary
- Fiscal year
- FY2024
Typical awards for this program (SAM.gov listing for ALN 93.103, not this notice): Varies by grant mechanism and program specific requirements.
Implied average = estimated total funding ÷ expected number of awards, calculated by GrantsJunction. Actual awards vary.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public colleges & universities
- Federally recognized tribal governments
- Public & Indian housing authorities
- Native American tribal organizations
- 501(c)(3) nonprofits
- Nonprofits without 501(c)(3) status
- Private colleges & universities
- For-profit organizations (not small businesses)
- Small businesses
A quick check against the listed applicant types — other requirements in the notice still apply.
Based on the published notice. Review the official notice for complete eligibility requirements.
What it funds
Official synopsis as published by the agency, formatted for readability.
Computational fluid dynamics (CFD) has played a crucial role in providing an alternative bioequivalence (BE) approach for generic orally inhaled drug products (OIDPs), in addition to comparative clinical endpoint or pharmacodynamic BE studies, as a relatively cost- and time-efficient complement to benchtop and clinical experiments that has been widely used in developing and assessing generic inhaler devices. However, despite the advances in the power of modern computers, there are still some bottlenecks in using CFD due to computational time, limited grid resolution, pre- and post-processing of large simulation data sets, model parameter estimations, and uncertainty quantifications. Machine learning (ML) has been gaining more attention as a potential tool to alleviate such limitations that arise in CFD. The purpose of this grant is to develop a methodology to integrate ML with CFD models of OIDPs to promote alternative BE studies to enhance and accelerate the development and approval of generic OIDPs.
How to apply
0 of 8 done · progress saved in this browser
Assistance Listing
What is an ALN?Reported obligations under ALN 93.103
Historical data · not a predictionWho was funded under ALN 93.103
Historical data · not a predictionSince October 1, 2023, 991 grant awards had funding actions under Food and Drug Administration Research, with 430 sub-awards passed on to other organizations. These are program-wide awards, not awards from this specific notice.
- THE CRITICAL PATH INSTITUTE$56.2M
- NATIONAL ENVIRONMENTAL HEALTH ASSOCIATION$39.7M
- ASSOCIATION OF FOOD & DRUG OFFICIALS$29.5M
- DUKE UNIVERSITY$19.1M
- THE MEDICAL DEVICE INNOVATION CONSORTIUM$15.6M
Agency contact (as published)
Terrin Brown Grants Management Specialist
terrin.brown@fda.hhs.gov
240-402-7610
Quick answers
Is this opportunity open for applications yet?
Not yet. It is a forecast — an agency's advance notice of an expected opportunity. Forecast details and dates can change.
Who is eligible to apply for this opportunity?
The official notice names these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 2 more. Additional restrictions may apply; review the full notice.
How much funding is available through this opportunity?
Per the notice, total estimated program funding is $600,000 and the agency expects to make about 1 awards.
How do I apply for this opportunity?
Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity FOR-FD-24-001), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.
Related open opportunities
Matched on shared Assistance Listings, agency, categories and eligible applicant types.
Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional
Food and Drug Administration- Award range
- Up to $300K
- Est. close
- Not yet set
- Who can apply
- State governments, County governments, City or township governments and 12 more
Minor Use Minor Species Development of Drugs (R01)
Food and Drug Administration- Award range
- Up to $250K
- Closes
- Jan 29, 2027
- Who can apply
- State governments, County governments, City or township governments and 12 more
Reissue of RFA-FD-23-001- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
Food and Drug Administration- Award range
- Up to $900K
- Closes
- May 16, 2028
- Who can apply
- Others (see notice)
Reducing Fraud and Lowering Barriers to the Production of Drugs in Shortage by Outsourcing Facilities
Food and Drug Administration- Award range
- Up to $3M
- Est. close
- Not yet set
- Who can apply
- Others (see notice)
Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
Food and Drug Administration- Award range
- Amount not specified
- Est. close
- Not yet set
- Who can apply
- Others (see notice)
Center for Research on Complex Generics (U18) Clinical Trials Optional
Food and Drug Administration- Award range
- $1.5M
- Est. close
- Not yet set
- Who can apply
- State governments, County governments, City or township governments and 12 more